Premium
Current status of antibody therapy in ALL
Author(s) -
Ai Jing,
Advani Anjali
Publication year - 2015
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.13205
Subject(s) - cd52 , alemtuzumab , blinatumomab , medicine , ofatumumab , rituximab , cd20 , antibody , immunology , cd19 , cd22 , antigen , oncology
Summary Despite the significant advances in modern chemotherapy, it remains challenging to treat adult patients with acute lymphoblastic leukaemia ( ALL ). The relapse rate remains high, and the outcome at the time of relapse is dismal. Antibody‐based therapies have demonstrated promising results in this patient group. Variable mechanisms have been applied to target surface antigens ( CD 20 [also termed MS 4A1], CD 22, CD 52 and CD 19) that are commonly expressed on malignant leukaemia cells. In this review, we will focus on the clinical application of such therapies in adult ALL , including the naked antibodies: Rituximab, Ofatumumab, Epratuzumab and Alemtuzumab; the immunotoxins: BL 22 and Combotox; the immunoconjugates: inotuzumab and SAR 3419; as well as the Bi‐specific T cell engaging (Bi TE )‐specific antibody, Blinatumomab.